Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy

被引:3
|
作者
Neutel, Joel [1 ]
Shojaee, Ali [2 ]
Maa, Jen-Fue [2 ]
机构
[1] Orange Cty Res Ctr, Dept Clin Pharmacol, Tustin, CA 92780 USA
[2] Daiichi Sankyo Inc, Parsippany, NJ USA
关键词
Amlodipine; Angiotensin II receptor blocker; Blood pressure; Calcium channel blocker; Combination therapy; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; OLMESARTAN MEDOXOMIL; BLOOD-PRESSURE; COMBINATION; AMLODIPINE; TRIAL;
D O I
10.1007/s12325-012-0030-z
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
While monotherapy is often recommended as initial treatment, most patients require dose escalation and add-on agents to achieve their blood pressure (BP) goal. This secondary analysis evaluated the efficacy and safety of initiating patients on a regimen of fixed-dose amlodipine (AML)/olmesartan medoxomil (OM) +/- hydrochlorothiazide (HCTZ) who were uncontrolled on prior monotherapy with a calcium channel blocker (CCB) or angiotensin II receptor blocker (ARB). Patients uncontrolled on prior monotherapy with CCB or ARB therapy were initiated on AML/OM 5/20 mg and up-titrated every 4 weeks to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 + HCTZ 12.5 mg, and AML/OM 10/40 + HCTZ 25 mg. Patients were up-titrated to a higher AML/OM dose if mean seated cuff BP (SeBP) was a parts per thousand yen120/70 mmHg, and up-titrated to any HCTZ dose if mean SeBP was a parts per thousand yen125/75 mmHg. The primary efficacy endpoint was the cumulative proportion of patients achieving a seated cuff systolic BP (SeSBP) goal of < 140 mmHg (< 130 mmHg for patients with diabetes) after 12 weeks. Secondary endpoints included mean change from baseline in SeBP and ambulatory BP, ambulatory BP target achievement, and safety. For the prior CCB (n = 118; baseline SeBP: 153.4/91.5 mmHg) and ARB (n = 237; 154.6/92.6 mmHg) groups, SeSBP goal achievement after 12 weeks was 72.7% and 76.9%, respectively. Mean changes (+/- SE) from baseline in SeBP were dose proportional for prior CCB and ARB patients, ranging from -9.9 (+/- 1.25)/-5.8 (+/- 0.83) mmHg and -13.9 (+/- 0.79)/-7.6 (+/- 0.47) mmHg at the AML/OM 5/20 mg dose, respectively, to -21.8 (+/- 1.68)/-11.6 (+/-.12) mmHg and -26.2 (+/- 1.31)/-15.0 (+/- 0.86) mmHg at the AML/OM 10/40 mg + HCTZ 25 mg dose (P < 0.0001 for all). An AML/OM-based titration regimen was efficacious in achieving BP goal in patients uncontrolled on prior monotherapy with a CCB or ARB.
引用
收藏
页码:508 / 523
页数:16
相关论文
共 50 条
  • [41] Comparison of angiotensin-receptor blocker and calcium channel blocker of morning blood pressure
    Eguchi, K
    Kario, K
    Ishikawa, J
    Hoshide, S
    Shimada, K
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 57A - 57A
  • [42] Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme
    Jun Agata
    Nobuyuki Ura
    Hideaki Yoshida
    Yasuyuki Shinshi
    Haruki Sasaki
    Masaya Hyakkoku
    Shinya Taniguchi
    Kazuaki Shimamoto
    Hypertension Research, 2006, 29 : 865 - 874
  • [43] Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme
    Agata, Jun
    Ura, Nobuyuki
    Yoshida, Hideaki
    Shinshi, Yasuyuki
    Sasaki, Haruki
    Hyakkoku, Masaya
    Taniguchi, Shinya
    Shimamoto, Kazuaki
    HYPERTENSION RESEARCH, 2006, 29 (11) : 865 - 874
  • [44] Olmesartan is an angiotensin II receptor blocker with an inhibitory effect of angiotensin-converting enzyme
    Agata, Jun
    Ura, Nobuyuki
    Yoshida, Hideaki
    Shinshi, Yasuyuki
    Sasaki, Haruki
    Hyakkoku, Masaya
    Taniguchi, Shinya
    Shimamoto, Kazuaki
    JOURNAL OF HYPERTENSION, 2006, 24 : 208 - 208
  • [45] The combination therapy of angiotensin II receptor blocker, calcium channel blocker and β blocker is important to control blood pressure in patients with chronic phase of aortic dissection and aneurysm
    Yamagishi, Toshio
    Sekin, Yoshihito
    JOURNAL OF HYPERTENSION, 2006, 24 : 367 - 367
  • [46] RANDOMIZED COMPARISON OF SYSTOLIC BLOOD PRESSURE VARIABILITY IN ESSENTIAL HYPERTENSIVE PATIENTS TREATED WITH A CALCIUM CHANNEL BLOCKER (AMLODIPINE) OR ANGIOTENSIN II RECEPTOR BLOCKER (LOSARTAN) - COMPASS BPV INTERIM ANALYSIS
    Lee, Jun-Won
    Choi, Eunhee
    Lee, Ji Hyun
    Youn, Young Jin
    Ahn, Sung Gyun
    Ahn, Min-Soo
    Kim, Jang-Young
    Lee, Seung-Hwan
    Yoon, Junghan
    Ryu, Dong Ryeol
    Hong, Kyung-Soon
    Yoo, Byung-Su
    JOURNAL OF HYPERTENSION, 2016, 34 : E295 - E295
  • [47] Efficacy of angiotensin II receptor blocker for the prophylaxis of migraine in Japanese patients
    Iigaya, M
    Sakai, F
    CEPHALALGIA, 2005, 25 (10) : 948 - 948
  • [48] Angiotensin Receptor Blocker Improves Coronary Flow Velocity Reserve in Hypertensive Patients: Comparison with Calcium Channel Blocker
    Fumihiko Kamezaki
    Hiromi Tasaki
    Kazuhito Yamashita
    Kiyoko Shibata
    Noriko Hirakawa
    Masato Tsutsui
    Ryouji Kouzuma
    Toshihisa Nagatomo
    Tetsuo Adachi
    Yutaka Otsuji
    Hypertension Research, 2007, 30 : 699 - 706
  • [49] Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: Comparison with calcium channel blocker
    Kamezaki, Fumihiko
    Tasaki, Hiromi
    Yamashita, Kazuhito
    Shibata, Kiyoko
    Hirakawa, Noriko
    Tsutsui, Masato
    Kouzuma, Ryouji
    Nagatomo, Toshihisa
    Adachi, Tetsuo
    Otsuji, Yutaka
    HYPERTENSION RESEARCH, 2007, 30 (08) : 699 - 706
  • [50] Effects of angiotensin-II receptor blocker or calcium channel blocker on abdominal aortic aneurysm growth at presurgical stage
    Murohara, T. M.
    Bando, Y. Kureishi
    Nishigami, K. N.
    Hirakawa, A. H.
    Taguchi, E. T.
    Iida, M. I.
    Nanasato, M.
    Kamiya, H. K.
    Komori, K. N.
    EUROPEAN HEART JOURNAL, 2015, 36 : 880 - 881